Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review

IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2024-01-31 DOI:10.2144/fsoa-2023-0074

Emilie Adrian Christiansen, I. Kümler

引用次数: 0

Abstract

Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this review we assess existing literature concerning real-world effectiveness of palbociclib. Survival outcomes in terms of progression-free survival and overall survival are discussed and compared among the included real-world studies and in relation to the phase III PALOMA trials.

查看原文本刊更多论文

palbociclib对HR+/HER2-转移性乳腺癌的实际疗效：文献综述

新确诊的乳腺癌中约有 70% 属于 HR+/HER2- 亚型。对于HR+/HER2-转移性乳腺癌患者的治疗，现行指南推荐使用CDK4/6抑制剂（palbociclib、ribociclib或abemaciclib）联合内分泌治疗。在这篇综述中，我们评估了有关帕博西尼（palbociclib）实际疗效的现有文献。我们讨论了无进展生存期和总生存期方面的生存结果，并对纳入的真实世界研究以及与 III 期 PALOMA 试验相关的研究进行了比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries